449 results on '"Kammerlander, Andreas A."'
Search Results
52. Right Atrial Phasic Function in Heart Failure with Preserved Ejection Fraction: Cardiac Magnetic Resonance Feature Tracking and Outcomes
53. Myocardial structural and functional changes in cardiac amyloidosis - Insights from a prospective observational patient registry
54. Quantitative Fluid Overload in Severe Aortic Stenosis Refines Cardiac Damage and Associates with Worse Outcomes
55. Kiosk 2R-FC-06 - Hepatic t1-time Predicts Cardiovascular Risk in All-comers - Congestion Is Not All of It
56. CMR 3-101 - Association Between Tricuspid Regurgitation Severity and CMR Derived Hepatic T1 Times and Survival
57. T1 Mapping by CMR Imaging: From Histological Validation to Clinical Implication
58. Angs (Angiotensins) of the Alternative Renin-Angiotensin System Predict Outcome in Patients With Heart Failure and Preserved Ejection Fraction
59. Serum levels of gamma-glutamyltransferase predict outcome in heart failure with preserved ejection fraction
60. Improvement of Symptoms and Cardiac Magnetic Resonance Abnormalities in Patients with Post-Acute Sequelae of SARS-CoV-2 Cardiovascular Syndrome (PASC-CVS) after Guideline-Oriented Therapy.
61. Prognostic Significance and Determinants of the 6-Min Walk Test in Patients With Heart Failure and Preserved Ejection Fraction
62. Erratum to: Outcomes of anatomical vs. functional testing for coronary artery disease: Lessons from the major trials
63. A streamlined, machine learning-derived approach to risk-stratification in heart failure patients with secondary tricuspid regurgitation
64. Monitoring of mitral‐ and tricuspid valve interventions with CardioMEMS : Insights beyond imaging
65. Assessment of Physical Performance in Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy Evaluated by Cardiopulmonary Exercise Testing – A Long-Term Follow-Up Study
66. Patient Selection and Clinical Indication for Chronic Total Occlusion Revascularization—A Workflow Focusing on Non-Invasive Cardiac Imaging
67. What is normal? A central question in the application of CMR mapping techniques
68. Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction: Study protocol for a randomized controlled trial
69. Bioimpedance Spectroscopy Reveals Important Association of Fluid Status and T 1 ‐Mapping by Cardiovascular Magnetic Resonance
70. Incidence, causes, correlates, and outcome of bioprosthetic valve dysfunction and failure following transcatheter aortic valve implantation
71. Unveiling Cardiac Amyloidosis, its Characteristics, and Outcomes Among Patients With MR Undergoing Transcatheter Edge-to-Edge MV Repair
72. The Complexity of Subtle Cardiac Tracer Uptake on Bone Scintigraphy
73. Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial
74. Prevalence and Outcomes of Cardiac Amyloidosis in All-Comer Referrals for Bone Scintigraphy
75. Invasive Hemodynamic Assessment and Procedural Success of Transcatheter Tricuspid Valve Repair—Important Factors for Right Ventricular Remodeling and Outcome
76. Comparison of Hepatic Tissue Characterization between T1-Mapping and Non-Contrast Computed Tomography
77. Bioimpedance Spectroscopy Reveals Important Association of Fluid Status andT 1‐Mapping by Cardiovascular Magnetic Resonance
78. HEPATIC T1-TIMES ON CARDIOVASCULAR MAGNETIC RESONANCE IMAGING REFLECT LIVER FIBROSIS AND PREDICT OUTCOME IN AN ALL-COMER COHORT
79. Referee report. For: Case Report: Aortic to right ventricular fistula after TAVR in a patient with transthyretin cardiac amyloidosis [version 1; peer review: 1 approved with reservations]
80. Economic growth and pollution in different political regimes
81. 1389The role of the right ventricular insertion point in heart failure patients with preserved ejection fraction: Insights from a cardiovascular magnetic resonance study
82. Cerebral Protection in TAVR—Can We Do Without? A Real-World All-Comer Intention-to-Treat Study—Impact on Stroke Rate, Length of Hospital Stay, and Twelve-Month Mortality
83. Transcatheter Versus Surgical Valve Repair in Patients with Severe Mitral Regurgitation
84. Prognostic impact of left atrial function in heart failure with preserved ejection fraction in sinus rhythm vs. persistent atrial fibrillation
85. Convolutional Neural Networks for Fully Automated Diagnosis of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging
86. The right heart in heart failure with preserved ejection fraction: insights from cardiac magnetic resonance imaging and invasive haemodynamics
87. Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction
88. Patient Selection and Clinical Indication for Chronic Total Occlusion Revascularization—A Workflow Focusing on Non-Invasive Cardiac Imaging.
89. Bioimpedance Spectroscopy Reveals Important Association of Fluid Status and T1‐Mapping by Cardiovascular Magnetic Resonance.
90. Volume Status Impacts CMR–Extracellular Volume Measurements and Outcome in AS Undergoing TAVR
91. Abstract 10988: Prevalence and Outcomes of Cardiac Amyloidosis in All-Comer Referrals for Bone Scintigraphy
92. Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy
93. Heart failure with preserved ejection fraction after left‐sided valve surgery: prevalent and relevant
94. Impact of afterload and infiltration on coexisting aortic stenosis and transthyretin amyloidosis
95. Additional file 3 of Quantifying and communicating the burden of COVID-19
96. New risk stratification after colorectal polypectomy reduces burden of surveillance without increasing mortality
97. Clinical Impact of Pre-Procedural Percutaneous Coronary Intervention in Low- and Intermediate-Risk Transcatheter Aortic Valve Replacement Recipients
98. Sex Differences in the Associations of Visceral Adipose Tissue and Cardiometabolic and Cardiovascular Disease Risk: The Framingham Heart Study
99. Discordance of High-Sensitivity Troponin Assays in Patients With Suspected Acute Coronary Syndromes
100. Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.